ATE241385T1 - Rekombinante adenovirus-vakzinen - Google Patents
Rekombinante adenovirus-vakzinenInfo
- Publication number
- ATE241385T1 ATE241385T1 AT94305656T AT94305656T ATE241385T1 AT E241385 T1 ATE241385 T1 AT E241385T1 AT 94305656 T AT94305656 T AT 94305656T AT 94305656 T AT94305656 T AT 94305656T AT E241385 T1 ATE241385 T1 AT E241385T1
- Authority
- AT
- Austria
- Prior art keywords
- recombinant adenovirus
- cell mediated
- mediated immunity
- warm blooded
- blooded mammal
- Prior art date
Links
- 229940021704 adenovirus vaccine Drugs 0.000 title 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000024932 T cell mediated immunity Effects 0.000 abstract 2
- 101710172711 Structural protein Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 210000002845 virion Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Respiratory Apparatuses And Protective Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10523293A | 1993-08-11 | 1993-08-11 | |
| US27628994A | 1994-07-20 | 1994-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE241385T1 true ATE241385T1 (de) | 2003-06-15 |
Family
ID=26802374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94305656T ATE241385T1 (de) | 1993-08-11 | 1994-07-29 | Rekombinante adenovirus-vakzinen |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0638316B1 (de) |
| JP (1) | JPH07145079A (de) |
| KR (1) | KR100347220B1 (de) |
| AT (1) | ATE241385T1 (de) |
| AU (2) | AU6889194A (de) |
| BR (1) | BR9403202A (de) |
| CA (1) | CA2130202A1 (de) |
| DE (1) | DE69432730T2 (de) |
| DK (1) | DK0638316T3 (de) |
| ES (1) | ES2196018T3 (de) |
| FI (1) | FI113621B (de) |
| HU (1) | HUT69793A (de) |
| IL (1) | IL110560A (de) |
| NZ (1) | NZ264190A (de) |
| PT (1) | PT638316E (de) |
| SG (1) | SG43029A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837511A (en) * | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| CA2266656A1 (en) * | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
| US5849561A (en) * | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
| WO2001002607A1 (en) | 1999-07-06 | 2001-01-11 | Merck & Co., Inc. | Adenovirus carrying gag gene hiv vaccine |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| CA2467486A1 (en) | 2001-11-30 | 2003-06-12 | Isis Innovation Limited | Vaccine |
| US7524510B2 (en) | 2005-02-23 | 2009-04-28 | The Uab Research Foundation | Alkyl-glycoside enhanced vaccination |
| BRPI0504782A (pt) | 2005-11-01 | 2007-09-18 | Fundacao Oswaldo Cruz | adenovìrus recombinantes, processo de construção de adenovìrus recombinantes, composição de vacina contra toxoplasmose, e método de imunização contra infecções causadas pelo parasita t. gondii |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL76751A (en) * | 1984-11-01 | 1991-04-15 | American Home Prod | Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies |
| US4925784A (en) * | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
| ES2115622T5 (es) * | 1990-10-17 | 2003-03-16 | Us Health | Clones moleculares de hiv-1 y usos de los mismos. |
| AU9179891A (en) * | 1990-12-19 | 1992-07-22 | Epitope, Inc. | Hiv reverse transcriptase vaccine |
| DK0586076T3 (da) * | 1992-08-07 | 2003-10-20 | Wyeth Corp | Rekombinant adenovirus-vacciner |
-
1994
- 1994-07-29 DK DK94305656T patent/DK0638316T3/da active
- 1994-07-29 AT AT94305656T patent/ATE241385T1/de not_active IP Right Cessation
- 1994-07-29 DE DE69432730T patent/DE69432730T2/de not_active Expired - Fee Related
- 1994-07-29 ES ES94305656T patent/ES2196018T3/es not_active Expired - Lifetime
- 1994-07-29 PT PT94305656T patent/PT638316E/pt unknown
- 1994-07-29 EP EP94305656A patent/EP0638316B1/de not_active Expired - Lifetime
- 1994-07-29 SG SG1996002624A patent/SG43029A1/en unknown
- 1994-08-03 AU AU68891/94A patent/AU6889194A/en not_active Abandoned
- 1994-08-04 IL IL11056094A patent/IL110560A/en not_active IP Right Cessation
- 1994-08-04 FI FI943626A patent/FI113621B/fi active
- 1994-08-05 NZ NZ264190A patent/NZ264190A/en not_active IP Right Cessation
- 1994-08-08 CA CA002130202A patent/CA2130202A1/en not_active Abandoned
- 1994-08-08 HU HU9402309A patent/HUT69793A/hu unknown
- 1994-08-08 BR BR9403202A patent/BR9403202A/pt not_active Application Discontinuation
- 1994-08-08 JP JP6185752A patent/JPH07145079A/ja active Pending
- 1994-08-08 KR KR1019940019699A patent/KR100347220B1/ko not_active Expired - Fee Related
-
1997
- 1997-12-19 AU AU48506/97A patent/AU4850697A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HU9402309D0 (en) | 1994-10-28 |
| CA2130202A1 (en) | 1995-02-12 |
| HK1009934A1 (en) | 1999-06-11 |
| KR950005326A (ko) | 1995-03-20 |
| IL110560A (en) | 1998-10-30 |
| FI113621B (fi) | 2004-05-31 |
| ES2196018T3 (es) | 2003-12-16 |
| AU4850697A (en) | 1998-03-26 |
| KR100347220B1 (ko) | 2003-02-26 |
| NZ264190A (en) | 1997-06-24 |
| AU6889194A (en) | 1995-02-23 |
| HUT69793A (en) | 1995-09-28 |
| SG43029A1 (en) | 1997-10-17 |
| FI943626A0 (fi) | 1994-08-04 |
| DK0638316T3 (da) | 2003-09-22 |
| EP0638316B1 (de) | 2003-05-28 |
| FI943626L (fi) | 1995-02-12 |
| BR9403202A (pt) | 1995-04-11 |
| JPH07145079A (ja) | 1995-06-06 |
| PT638316E (pt) | 2003-10-31 |
| DE69432730T2 (de) | 2004-03-25 |
| EP0638316A1 (de) | 1995-02-15 |
| DE69432730D1 (de) | 2003-07-03 |
| IL110560A0 (en) | 1994-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69531297D1 (de) | Rekombinanter papillomavirus l1 | |
| PT101052A (pt) | Proteinas hibridas uteis na preparacao de vacinas | |
| GEP20084431B (en) | Papilloma virus vaccine | |
| EP1033995A4 (de) | Insektenzellen oder fraktionen als antigenadjuvanz | |
| PT586076E (pt) | Vacinas de adenovirus recombinantes | |
| DK0638316T3 (da) | Rekombinante adenovirusvacciner | |
| NZ238833A (en) | Equine herpesvirus-4 gh or gc polypeptides, nucleic acids encoding them and vaccines therefrom | |
| AU2403188A (en) | Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same | |
| DE69433760D1 (de) | Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält | |
| DK43991D0 (da) | Allele varianter af plasmodium falciparum merozoitoverfladeantigen | |
| GB2244273A (en) | Allelic variants of plasmodium falciparum merozoite surface antigen. | |
| MY106940A (en) | Allelic variants of plasmodium falciparum merozoite surface antigen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0638316 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |